INSILICO (03696) expands AI-driven R&D cooperation in the CNS field with YuanYi Biotechnology. The total amount of the new cooperation can reach up to 94.75 million US dollars.
England Silicon Intelligence (03696) announced that, based on the good cooperation relationship in the past year, England Silicon Intelligence has reached an extended AI-driven research and development partnership with Tenacia Biotechnology (Hongkong) Co., Limited (Yuan Yi Biology), a commercial biopharmaceutical company dedicated to developing innovative treatment solutions for underserved neurological disease patients.
INSILICO (03696) announced that, based on the good partnership over the past year, INSILICO has reached an expanded AI-driven research and development collaboration with Tenacia Biotechnology (Hongkong) Co., Limited (Yuan Yi Biotech), a commercial biopharmaceutical company dedicated to developing innovative treatment solutions for unmet neurological diseases.
Through this collaboration, both parties aim to provide broader and more precise treatment options for challenging neurological diseases, ultimately reducing late-stage development risks and enhancing potential clinical benefits.
Under the agreement, both parties will utilize generative AI to jointly develop a novel candidate molecule with specific attributes targeting challenging neurological diseases and advance it to the preclinical candidate compound (PCC) stage to meet differentiated clinical needs. The total transaction amount for this expanded collaboration could reach up to $94.75 million. INSILICO is expected to receive payments from Yuan Yi Biotech for upcoming and milestone payments.
Related Articles
HK Stock Market Move | CHERVON (02285) plunges over 20% after performance announcement, with net profit dropping by 13.2% year-on-year. Proposed final dividend of 44.69 Hong Kong cents.
HK Stock Market Move | XUANZHUBIO-B(02575) rose more than 18% in early trading. The Phase III clinical trial results of Piloselyl BRIGHT-2 were published in the top journal of Xi'An International Medical Investment.
HK Stock Market Move | CHINARES PHARMA (03320) continues to rise by more than 4%, with a year-on-year increase in net profit of over 20%. Final dividends have doubled compared to last year.
HK Stock Market Move | CHERVON (02285) plunges over 20% after performance announcement, with net profit dropping by 13.2% year-on-year. Proposed final dividend of 44.69 Hong Kong cents.
HK Stock Market Move | XUANZHUBIO-B(02575) rose more than 18% in early trading. The Phase III clinical trial results of Piloselyl BRIGHT-2 were published in the top journal of Xi'An International Medical Investment.
HK Stock Market Move | CHINARES PHARMA (03320) continues to rise by more than 4%, with a year-on-year increase in net profit of over 20%. Final dividends have doubled compared to last year.
